slides · global inventory
Scqa Framework
Tool collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 352
Current window 301-330
Pages 12
Rows per page 30
Tool
301-330 of 352
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
44
The slide uses a Venn diagram to illustrate target overlap and a tree diagram to show potential combination therapy paths.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
14
The slide outlines a clinical trial protocol timeline.argenx SE | Investor Presentation Deck | 25 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
29
The slide uses a three-column layout to categorize decarbonization efforts into specific scopes and programs.AstraZeneca | Results Presentation Deck | 44 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
24
Includes definitions for PK/PD, qEEG, and BID in the footer.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
29
The slide uses a standard clinical trial flow diagram showing randomization into three arms (40mg, 20mg, placebo) over a 6-week period.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
Includes multiple charts showing inhibition of cytokines and reduction of inflammation.BenevolentAI | Investor Presentation Deck | 46 slides · BenevolentAI
Pitch deck Investor relations 1 hit
27
The slide uses a table to present clinical outcomes (PR/CR) for specific tumor types, supporting the 'first-in-class' claim.BioAtla | Investor Presentation Deck | 40 slides · BioAtla
Pitch deck Investor relations 1 hit
16
Includes FDA Fast Track and Breakthrough Therapy designations.CG Oncology | IPO Presentation Deck | 45 slides · CG Oncology
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
26
The slide outlines a standard Simon 2-stage design where recruitment stops if the objective response rate (ORR) threshold is not met in the first stage.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
The slide highlights statistically significant improvements (p<0.01) across multiple clinical endpoints.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strategy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
48
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
10
The slide outlines the trial parameters (n=27) and highlights the transition to the OnPrime Phase 3 trial.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
05
The diagram uses a bullseye/concentric circle framework to show the hierarchy from disease down to the molecular level.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
23
The slide outlines a randomized clinical trial structure with a 1:1:1:1 ratio, a 12-month treatment period, and a 1-month follow-up.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
29
Includes specific stopping rules for futility based on Disease Control Rate (DCR).Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
68
The slide uses a stacked bar chart representation to show the relative scale of investment needs across different sectors.HSBC | Investor Event Presentation Deck | 80 slides · HSBC
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
51
Includes technical diagrams of the drug delivery vehicle and comparative histology/survival data.Immix Biopharma | Investor Presentation Deck | 61 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
37
The slide lists various sustainability initiatives (SBTi, Fashion Pact, RE100, CDP, TCFD) alongside specific quantitative reduction targets.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
40
Includes a visual comparison of land footprint vs. restoration target.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Key TakeawaysLoop · Cost Of Inaction1 hit
16
The slide outlines a non-inferiority trial design comparing oral MAT2203 to IV LAMB/SoC.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
14
The slide uses a timeline-based diagram to illustrate the clinical trial protocol.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a side-by-side comparison layout to distinguish between the dose escalation (Phase 1) and the registrational intent (Phase 2) study designs.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
20
Includes two distinct experimental setups: in vitro proliferation assays and in vivo bioluminescence imaging (BLI) tumor growth studies.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
15
The slide illustrates the genetic mechanism of the platform, showing how human V, D, and J genes are combined with rat constant regions to facilitate robust immune responses, followed by conversion to fully human antibodies.OmniAb | Investor Presentation Deck | 35 slides · OmniAb
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes a comparison of three generations of CD40L antibodies and a structural diagram of the antibody.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
09
The chart shows a comparison of simulated thyroxine concentrations over 7 days.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit